Patents by Inventor David J. Hackam

David J. Hackam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20210308162
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: February 11, 2021
    Publication date: October 7, 2021
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Chhinder P. Sodhi, David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 10933077
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 2, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Chhinder P. Sodhi, David J. Hackam
  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20190374562
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 12, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 10300083
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 28, 2019
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • GAP JUNCTION-ENHANCING AGENTS FOR TREATMENT OF NECROTIZING ENTEROCOLITIS AND INFLAMMATORY BOWEL DISEASE
    Publication number: 20190070168
    Abstract: The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 7, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: David J. Hackam
  • Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
    Patent number: 10172848
    Abstract: The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: January 8, 2019
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEMS OF HIGHER EDUCATION
    Inventor: David J. Hackam
  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20170095493
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Oral therapy of necrotizing enterocolitis
    Patent number: 9562066
    Abstract: The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: February 7, 2017
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventor: David J. Hackam
  • Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists
    Patent number: 9549980
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: January 24, 2017
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventor: David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 9532999
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 3, 2017
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • METHODS OF TREATING NECROTIZING ENTEROCOLITIS BY ADMINISTERING NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS,TLR9 AGONISTS AND TLR4 ANTAGONISTS
    Publication number: 20160303229
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Application
    Filed: August 26, 2013
    Publication date: October 20, 2016
    Applicant: University of Pittsburgh - of the Commonwealth System of Highter Education
    Inventor: DAVID J. HACKAM
  • NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS
    Publication number: 20150250809
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
    Patent number: 9072760
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: July 7, 2015
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OR PREVENTION OF TOLL-LIKE RECEPTOR-4 ASSOCIATED DISORDERS
    Publication number: 20150056217
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 26, 2015
    Applicant: University of Pittsburgh - of the Commonwealth System of Highter Education
    Inventor: DAVID J. HACKAM
  • ORAL THERAPY OF NECROTIZING ENTEROCOLITIS
    Publication number: 20140086982
    Abstract: The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants.
    Type: Application
    Filed: September 25, 2013
    Publication date: March 27, 2014
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: David J. Hackam
  • Gap Junction-Enhancing Agents for Treatment of Necrotizing Enterocolitis and Inflammatory Bowel Disease
    Publication number: 20130345154
    Abstract: The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 26, 2013
    Inventor: David J. Hackam
  • Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment of prevention of toll-like receptor-4-associated disorders
    Patent number: 8518905
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: August 27, 2013
    Assignee: University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: David J. Hackam, Steven C. Gribar
  • Use of toll-like receptor-9 agonists
    Patent number: 8518903
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: August 27, 2013
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventor: David J. Hackam
  • USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OF PREVENTION OF TOLL-LIKE RECEPTOR-4-ASSOCIATED DISORDERS
    Publication number: 20130072547
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Application
    Filed: May 1, 2012
    Publication date: March 21, 2013
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH OF HIGHER EDUCATION
    Inventors: DAVID J. HACKAM, STEVEN C. GRIBAR
  • Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
    Patent number: 8188058
    Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: May 29, 2012
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: David J. Hackam, Steven C. Gribar